Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
75%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

unknown125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completednot_applicable

The Added Value of Contrast Enhancement for Guiding EUS-FNA in Solid Pancreatic Masses

NCT03525847
completednot_applicable

To Compare EUS and MRCP in Detecting Choledocholithiasis in Patients of Intermediate Risk of Choledocholithiasis

NCT04173624
unknownnot_applicable

EBUS vs EUS-B for Diagnosing Sarcoidosis

NCT02540694
completed

Single Scope Staging of Lung Cancer With Endosonography

NCT02014324

Clinical Trials (4)

Showing 4 of 4 trials
NCT03525847Not Applicable

The Added Value of Contrast Enhancement for Guiding EUS-FNA in Solid Pancreatic Masses

Completed
NCT04173624Not Applicable

To Compare EUS and MRCP in Detecting Choledocholithiasis in Patients of Intermediate Risk of Choledocholithiasis

Completed
NCT02540694Not Applicable

EBUS vs EUS-B for Diagnosing Sarcoidosis

Unknown
NCT02014324

Single Scope Staging of Lung Cancer With Endosonography

Completed

All 4 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
4